View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
ACR Open Rheumatol. 2023;5(7):345-353 doi 10.1002/acr2.11577
Cicirello, et al. present results showing that baricitinib is comparable in treatment persistence with TNF inhibitors. However, treatment persistence up to 24 months was significantly longer for baricitinib, but the effect size of one month is not clinically meaningful.
N Engl J Med 2023;388(26):2444–2455 doi: 10.1056/NEJMoa2207940
Mirikizumab was more effective than placebo in inducing and maintaining clinical remission in patients with moderately to severely active ulcerative colitis. D’Haens, et al. also noted that opportunistic infections and cancer developed in a small number of mirikizumab-treated patients.
Int J Rheum Dis. 2023;26(9):1729–1736 doi: 10.1111/1756-185X.14801
This single-centre study by Khan, et al. suggests that high-dose methotrexate (25 mg/week, subcutaneously) may be as efficacious as tofacitinib in patients with established RA who are DMARD naïve or have not received a therapeutic dose of DMARDs.
Rheumatol Ther. 2023;10(4):849-860 doi: 10.1007/s40744-023-00548-y
Secukinumab reduced disease activity across a range of outcome measures by week 12, with sustained responses through 52 weeks.
Arthritis Res Ther. 2023;16;25(1):80 doi 10.1186/s13075-023-03051-5
Braun et al. studied a large cohort of patients with nr-axSpA, that demonstrated a secukinumab reduced SI joint inflammation (BME), this reduction was sustained over 104 weeks, from an overall low baseline level of spinal inflammation or structural damage.
Arthritis Rheumatol. 2023 doi 10.1002/art.42617 Epub ahead of print
The results from Simon, et al. show that baricitinib treatment correlates with improvements in bone stiffness. Further improvements were also observed at the end of Week 52, with an increase in estimated failure load and no measurable progression in bone erosion being reported.
Ann Rheum Dis 2023;82:1049–1058
Reinisch, et al. show that filgotinib treatment has no effect on semen parameters for men with active inflammatory diseases. This contrasts with pre-clinical studies that showed fertility issues in male animals.
Rheumatol Ther 2023;10(4):1073–1087 doi 10.1007/s40744-023-00570-0
Kristensen, et al. used mediation modelling to show that tofacitinib indirectly improved fatigue symptoms via back pain and morning stiffness. This study was carried out using FACIT-F- and BASDAI Q1-based models to determine the relationship between these variables.
Rheumatol Ther. 2023;10(4):1001–1020 doi 10.1007/s40744-023-00564-y
Tofacitinib treatment is associated with a significant improvement in CANDEN MRI scores of spinal inflammation in axSpA patients. This study by Østergaard, et al. also validates the CANDEN MRI scoring system as an approach for measuring axSpA-associated inflammatory lesions.
Mod Rheumatol 2023;34(3):453–65 doi: 10.1093/mr/road059
Pots hoc analysis of peficitinib Phase 3 trials shows that continued treatment with peficitinib up to Week 52 is linked to improved remission rates in Asian patients with RA.
